Using high-dose, high-precision radiation therapy to treat renal cell carcinoma (RCR) is safe for patients with one kidney, according to findings presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas.

Black men with prostate cancer may have “comparatively higher” cure rates than white men when treated with radiation therapy, according to study results presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Among women receiving radiation therapy to treat early-stage breast cancer, receiving larger individual doses was not associated with a significant increase in long-term side effects, according to a 10-year study presented Oct. 21 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Radiation therapy can lower the chance of cancer recurrence in patients with low-risk breast cancer following breast conservation surgery, according to data presented Oct. 21 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

Architectural distortion, the non-mass but potentially ominous clinical feature observed in many breast imaging procedures, is less likely to signal malignancy when it’s detected on screening mammography rather than diagnostic mammography or when it does not correlate with a subsequent targeted ultrasound exam.